Most of the drugs and APIs currently on the market are poorly water-soluble and need to have their bioavailability improved through the development of enabled formulations and patient-centric delivery mechanisms. Despite the promises of many “next generation” techniques, the biopharma industry continues to rely on refinements to amorphous solid dispersions and hot melt extrusions. Formulation professionals will continue to face challenges in the solubility and characterization of these drug delivery methods for years to come.
Now in its seventh year, the Drug Formulation, Solubility and Bioavailability conference is geared toward improving drug performance and therapeutic impact through enabled formulations and more effective delivery methods. By popular demand, this year’s event will feature a full-day seminar about improving the performance and modeling of amorphous solid dispersions!
